MYRIAD GENETICS, INC. (NASDAQ:MYGN) Files An 8-K Regulation FD Disclosure

MYRIAD GENETICS, INC. (NASDAQ:MYGN) Files An 8-K Regulation FD Disclosure
ITEM 7.01

Story continues below

On March 14, 2019, Myriad Genetics, Inc. (Myriad or the Company) issued a press release announcing that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath Melanoma test.A copy of the press release announcing the LCD is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Safe Harbor Statement

This communication, including the exhibits attached hereto, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements.

Page 2

(d)

The exhibit(s) may contain hypertext links to information on our website or other parties websites. The information on our website and other parties websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 7.01 and in Exhibit 99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Page 3

MYRIAD GENETICS INC Exhibit
EX-99.1 2 mygn-ex991_6.htm EX-99.1 mygn-ex991_6.htm Exhibit 99.1 News Release   Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 rrogers@myriad.comsgleason@myriad.com     Myriad’s myPath® Melanoma Test Receives Medicare Coverage   Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy   SALT LAKE CITY,…
To view the full exhibit click here

About MYRIAD GENETICS, INC. (NASDAQ:MYGN)

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

An ad to help with our costs